ZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today presented first in vivo proof-of-concept data and additional in
ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the "Company")), a leading developer of next-generation antibody-based cancer therapies, today
Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the "Company")), a leading developer of next-generation antibody-based cancer therapies, today
ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in the design and development of next-generation cancer
ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio.
ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", )), an emerging leader in designing novel cancer therapies, today announced the advancement of
ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in the design and development of next-generation cancer therapeutics, held an
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel,
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA)), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German
ZURICH, SWITZERLAND – July 13, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven
ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. "In the first six
ZURICH, SWITZERLAND – July 02, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead
ZURICH, SWITZERLAND – June 24, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory
ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data
